Acquisition of 35.85% Stake in BioVille for 12.4 Billion Won via Litigation Settlement
-
Decision to acquire 5,509,953 shares (35.85%) of BioVille for 12.4 billion won as a result of litigation settlement
-
Payment in cash (3.5 billion won from escrow) and 15th convertible bonds (8.9 billion won)
-
BioVille had zero revenue and a net loss of 1.268 billion won in 2025
-
After acquisition, Korea Stem Cell Bank's stake in BioVille increases to 35.85%
KOSDAQ Filing Information
-
-
Decision on Acquisition of Stocks and Investment Securities of Other Corporations
-
Company: GemVax & KAEL (082270)
-
Submission: GemVax & KAEL Co.,Ltd.
-
Under KRX KOSDAQ Market Division
-
-
Shares: 44,269,203
-
Price: 25,350 KRW
-
Market Cap: 1,122.2 B KRW